| A339 |
SC-005 Biosimilar(Anti-Melanotransferrin / CD228 Reference Antibody)
Featured
|
|
|
| A340 |
RGX-019 Biosimilar(Anti-MER / MERTK Reference Antibody)
Featured
|
|
|
| A341 |
Amatuximab Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium. |
|
| A342 |
BMS-986148 Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
|
|
| A343 |
Anetumab Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor. |
|
| A344 |
NIH patent anti-Mesothelin Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
|
|
| A345 |
CLN-619 Biosimilar(Anti-MICA Reference Antibody)
Featured
|
|
|
| A346 |
U.Washington patent anti-MICB Biosimilar(Anti-MICB Reference Antibody )
Featured
|
|
|
| A347 |
Imalumab Biosimilar(Anti-MIF Reference Antibody)
Featured
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer. |
|
| A348 |
Andecaliximab Biosimilar(Anti-MMP9 Reference Antibody)
Featured
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF). |
|
| A349 |
Yeda patent anti-MMP-9 Biosimilar(Anti-MMP9 Reference Antibody)
Featured
|
|
|
| A350 |
TA136 Biosimilar(Anti-MPL / TPOR / CD110 Reference Antibody)
Featured
|
|
|
| A351 |
Copenhagen Rigshospitalet patent anti-uPARAP Biosimilar(Anti-MRC2 / CD280 Reference Antibody)
Featured
|
|
|
| A352 |
Quark patent anti-ENDO 180 Biosimilar（Anti-MRC2 / CD280 Reference Antibody）
Featured
|
|
|
| A353 |
Narnatumab Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer. |
|
| A354 |
Aveo anti-RON Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
|
|
| A355 |
H5B14 Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
|
|
| A356 |
Ensituximab Biosimilar（Anti-MU5AC Reference Antibody）
Featured
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer. |
|
| A357 |
Gatipotuzumab Biosimilar（Anti-MUC1 Reference Antibody）
Featured
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC). |
|
| A358 |
Clivatuzumab Biosimilar(Anti-MUC1 Reference Antibody)
Featured
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. |
|
| A359 |
Oregovomab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
|
|
| A360 |
Abagovomab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc). |
|
| A361 |
Sofituzumab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody. |
|
| A362 |
Forerunner patent anti-Muc 17 Biosimilar(Anti-MUC17 Reference Antibody)
Featured
|
|
|
| A363 |
Argenx patent anti-MuSK Biosimilar(Anti-MUSK Reference Antibody)
Featured
|
|
|
| A364 |
Alt-100 Biosimilar(Anti-NAMPT Reference Antibody)
Featured
|
|
|
| A365 |
Lifastuzumab Biosimilar(Anti-NaPi2b / SLC34A2 Reference Antibody)
Featured
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity. |
|
| A366 |
Upifitamab Biosimilar(Anti-NaPi2b / SLC34A2 Reference Antibody)
Featured
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. |
|
| A367 |
Lorvotuzumab Biosimilar(Anti-NCAM1 / CD56 Reference Antibody)
Featured
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. |
|
| A368 |
Enfortumab Biosimilar(Anti-Nectin-4 Reference Antibody)
Featured
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma. |
|
